Orthofix Medical Inc. (OFIX) 10-Year Financial Performance & Capital Metrics

OFIX • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesSpinal Implants & Fusion Systems

AboutOrthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.Show more

Revenue $799M +7.1%
EBITDA -$25M +68.7%
Net Income -$126M +16.8%
EPS (Diluted) -3.30 +19.9%
Gross Margin 68.28% +4.8%
EBITDA Margin -3.07% +70.8%
Operating Margin -10.58% +43.2%
Net Margin -15.76% +22.3%
ROE -22.87% +29.3%
ROIC -9.9% +53.0%
Debt/Equity 0.36 +82.6%
Interest Coverage -2.86 +82.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 11.7%
✓Trading at only 1.1x book value

✗Weaknesses

✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y7.11%

5Y11.69%

3Y19.84%

TTM4.31%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.5%

ROCE

10Y Avg-1.62%

5Y Avg-8.61%

3Y Avg-13.16%

Latest-11.4%

Peer Comparison

Spinal Implants & Fusion Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GMEDGlobus Medical, Inc.	10.46B	93.89	125.19	60.62%	15.3%	9.63%	3.87%	0.13
TNONTenon Medical, Inc.	10.6M	0.95	-0.08	11.92%	-396.26%	-267.01%		0.07
BBLGBone Biologics Corporation	3M	1.67	-0.35			-65.59%
OFIXOrthofix Medical Inc.	570.24M	14.40	-4.36	7.08%	-14.56%	-26.92%		0.36
XTNTXtant Medical Holdings, Inc.	91M	0.65	-5.42	28.44%	1.32%	3.48%		0.82
ATECAlphatec Holdings, Inc.	2.59B	17.46	-15.45	26.81%	-21.29%	-13.47%		64.65
SIBNSI-BONE, Inc.	762.82M	17.58	-23.44	20.37%	-11.24%	-12.64%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	396.49M	409.79M	433.82M	453.04M	459.95M	406.56M	464.48M	460.71M	746.64M	799.49M
Revenue Growth %	-0.01%	0.03%	0.06%	0.04%	0.02%	-0.12%	0.14%	-0.01%	0.62%	0.07%
Cost of Goods Sold+	86.53M	87.85M	93.04M	96.63M	100.61M	101.89M	114.91M	123.54M	260.37M	253.61M
COGS % of Revenue	0.22%	0.21%	0.21%	0.21%	0.22%	0.25%	0.25%	0.27%	0.35%	0.32%
Gross Profit+	309.96M	321.94M	340.79M	356.41M	359.35M	304.67M	349.56M	337.17M	486.27M	545.88M
Gross Margin %	0.78%	0.79%	0.79%	0.79%	0.78%	0.75%	0.75%	0.73%	0.65%	0.68%
Gross Profit Growth %	0.02%	0.04%	0.06%	0.05%	0.01%	-0.15%	0.15%	-0.04%	0.44%	0.12%
Operating Expenses+	291.63M	284.49M	302.46M	323.25M	378.13M	310.94M	357.88M	350.44M	625.38M	630.5M
OpEx % of Revenue	0.74%	0.69%	0.7%	0.71%	0.82%	0.76%	0.77%	0.76%	0.84%	0.79%
Selling, General & Admin	265.24M	255.69M	272.76M	290.03M	309.28M	272.38M	290.67M	308.78M	530.39M	532.52M
SG&A % of Revenue	0.67%	0.62%	0.63%	0.64%	0.67%	0.67%	0.63%	0.67%	0.71%	0.67%
Research & Development	26.39M	28.8M	29.7M	33.22M	34.64M	39.06M	49.62M	49.06M	80.23M	73.64M
R&D % of Revenue	0.07%	0.07%	0.07%	0.07%	0.08%	0.1%	0.11%	0.11%	0.11%	0.09%
Other Operating Expenses	-259K	0	0	0	34.21M	-499K	17.59M	-7.4M	14.76M	24.34M
Operating Income+	9.26M	21.07M	40.81M	30.09M	-18.78M	-6.27M	-8.31M	-13.27M	-139.11M	-84.62M
Operating Margin %	0.02%	0.05%	0.09%	0.07%	-0.04%	-0.02%	-0.02%	-0.03%	-0.19%	-0.11%
Operating Income Growth %	-0.46%	1.28%	0.94%	-0.26%	-1.62%	0.67%	-0.33%	-0.6%	-9.48%	0.39%
EBITDA+	30.18M	41.91M	60.94M	48.75M	9.69M	28.01M	24.78M	18.81M	-78.55M	-24.56M
EBITDA Margin %	0.08%	0.1%	0.14%	0.11%	0.02%	0.07%	0.05%	0.04%	-0.11%	-0.03%
EBITDA Growth %	0.55%	0.39%	0.45%	-0.2%	-0.8%	1.89%	-0.12%	-0.24%	-5.18%	0.69%
D&A (Non-Cash Add-back)	20.92M	20.84M	20.12M	18.66M	28.48M	34.28M	33.1M	32.08M	60.56M	60.06M
EBIT	9.26M	35.44M	40.81M	22.89M	-26.93M	2.12M	-11.66M	-16.42M	-140.05M	-94.24M
Net Interest Income+	-489K	763K	-416K	-828K	-122K	-2.48M	-1.84M	-1.29M	-8.63M	-29.63M
Interest Income	0	763K	0	0	0	0	0	0	0	0
Interest Expense	489K	0	416K	828K	122K	2.48M	1.84M	1.29M	8.63M	29.63M
Other Income/Expense	-748K	-2.04M	-4.42M	-7.21M	-8.27M	5.9M	-5.18M	-4.44M	-9.57M	-39.26M
Pretax Income+	8.51M	19.02M	36.39M	22.89M	-27.05M	-368K	-13.49M	-17.71M	-148.68M	-123.88M
Pretax Margin %	0.02%	0.05%	0.08%	0.05%	-0.06%	-0%	-0.03%	-0.04%	-0.2%	-0.15%
Income Tax+	10.85M	15.53M	29.1M	9.07M	1.41M	-2.88M	24.88M	2.04M	2.72M	2.12M
Effective Tax Rate %	-0.33%	0.16%	0.17%	0.6%	1.05%	-6.84%	2.84%	1.12%	1.02%	1.02%
Net Income+	-2.81M	3.06M	6.22M	13.81M	-28.46M	2.52M	-38.38M	-19.75M	-151.4M	-126M
Net Margin %	-0.01%	0.01%	0.01%	0.03%	-0.06%	0.01%	-0.08%	-0.04%	-0.2%	-0.16%
Net Income Growth %	0.67%	2.09%	1.04%	1.22%	-3.06%	1.09%	-16.25%	0.49%	-6.67%	0.17%
Net Income (Continuing)	-2.34M	3.5M	7.29M	13.81M	-28.46M	2.52M	-38.38M	-19.75M	-151.4M	-126M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.15	0.17	0.34	0.73	-1.51	0.13	-1.95	-0.98	-4.12	-3.30
EPS Growth %	0.67%	2.13%	1%	1.15%	-3.07%	1.09%	-16%	0.5%	-3.2%	0.2%
EPS (Basic)	-0.15	0.17	0.34	0.75	-1.51	0.13	-1.95	-0.98	-4.12	-3.30
Diluted Shares Outstanding	18.8M	18.46M	18.5M	18.91M	18.9M	19.39M	19.69M	20.1M	36.73M	38.13M
Basic Shares Outstanding	18.8M	18.14M	18.12M	18.49M	18.9M	19.27M	19.69M	20.1M	36.73M	38.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	212.25M	194.37M	251.8M	244.64M	260.55M	270.38M	269.52M	255.99M	420.44M	433.29M
Cash & Short-Term Investments	63.66M	39.57M	81.16M	69.62M	69.72M	96.29M	87.85M	50.7M	33.11M	83.24M
Cash Only	63.66M	39.57M	81.16M	69.62M	69.72M	96.29M	87.85M	50.7M	33.11M	83.24M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	59.84M	57.85M	63.44M	77.75M	86.81M	72.42M	78.56M	82.86M	128.1M	134.71M
Days Sales Outstanding	55.09	51.53	53.37	62.64	68.88	65.02	61.73	65.64	62.62	61.5
Inventory	57.56M	63.35M	81.33M	76.85M	82.4M	84.64M	82.97M	100.15M	222.17M	189.45M
Days Inventory Outstanding	242.83	263.18	319.07	290.28	298.93	303.19	263.55	295.88	311.45	272.67
Other Current Assets	0	14.37M	0	2.57M	684K	530K	0	22.28M	37.07M	25.88M
Total Non-Current Assets+	187.97M	177.73M	153.55M	222M	235.07M	255.48M	207.1M	202.64M	504.87M	460.01M
Property, Plant & Equipment	52.31M	48.92M	45.14M	42.84M	62.73M	63.61M	59.25M	58.23M	159.06M	139.8M
Fixed Asset Turnover	7.58x	8.38x	9.61x	10.58x	7.33x	6.39x	7.84x	7.91x	4.69x	5.72x
Goodwill	53.56M	53.56M	53.56M	72.4M	71.18M	84.02M	71.32M	71.32M	194.93M	194.93M
Intangible Assets	5.3M	7.46M	10.46M	51.9M	54.14M	60.52M	52.67M	47.39M	117.49M	98.8M
Long-Term Investments	321K	321K	0	219K	0	0	0	0	0	0
Other Non-Current Assets	19.17M	20.14M	21.07M	21.42M	11.91M	22.29M	22.09M	25.7M	33.39M	26.47M
Total Assets+	400.22M	372.1M	405.35M	466.64M	495.62M	525.86M	476.62M	458.63M	925.32M	893.29M
Asset Turnover	0.99x	1.10x	1.07x	0.97x	0.93x	0.77x	0.97x	1.00x	0.81x	0.89x
Asset Growth %	0.02%	-0.07%	0.09%	0.15%	0.06%	0.06%	-0.09%	-0.04%	1.02%	-0.03%
Total Current Liabilities+	81.99M	83.44M	79.41M	85.91M	84.88M	103.9M	105.83M	83.62M	165.22M	168.63M
Accounts Payable	11.21M	14.35M	18.11M	17.99M	19.89M	23.12M	26.46M	27.6M	58.36M	48.8M
Days Payables Outstanding	47.28	59.63	71.05	67.95	72.15	82.82	84.04	81.54	81.81	70.24
Short-Term Debt	0	0	0	0	0	0	0	0	1.25M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	5.18M	3.54M	9.63M	46.31M	48.79M	24.73M	21.99M	0	1M	7.1M
Current Ratio	2.59x	2.33x	3.17x	2.85x	3.07x	2.60x	2.55x	3.06x	2.54x	2.57x
Quick Ratio	1.89x	1.57x	2.15x	1.95x	2.10x	1.79x	1.76x	1.86x	1.20x	1.45x
Cash Conversion Cycle	250.63	255.08	301.39	284.97	295.67	285.39	241.24	279.99	292.26	263.93
Total Non-Current Liabilities+	27.92M	25.18M	29.34M	45.34M	83.11M	65.1M	33.86M	38.15M	161.36M	221.54M
Long-Term Debt	0	0	0	0	0	0	0	0	93.11M	157.01M
Capital Lease Obligations	0	0	0	0	20.65M	22.34M	19.89M	19.24M	18.53M	17.84M
Deferred Tax Liabilities	0	0	0	0	11.99M	0	0	0	0	0
Other Non-Current Liabilities	27.92M	25.18M	29.34M	45.34M	62.46M	42.76M	13.97M	18.91M	49.72M	46.69M
Total Liabilities	109.91M	108.63M	108.75M	131.24M	167.99M	169M	139.69M	121.77M	326.58M	390.17M
Total Debt+	0	0	0	0	22.85M	24.94M	24.31M	21.53M	117.07M	179.63M
Net Debt	-63.66M	-39.57M	-81.16M	-69.62M	-46.87M	-71.35M	-63.53M	-29.17M	83.97M	96.39M
Debt / Equity	-	-	-	-	0.07x	0.07x	0.07x	0.06x	0.20x	0.36x
Debt / EBITDA	-	-	-	-	2.36x	0.89x	0.98x	1.14x	-	-
Net Debt / EBITDA	-2.11x	-0.94x	-1.33x	-1.43x	-4.84x	-2.55x	-2.56x	-1.55x	-	-
Interest Coverage	18.93x	-	98.10x	36.35x	-153.97x	-2.52x	-4.53x	-10.30x	-16.12x	-2.86x
Total Equity+	290.31M	263.48M	296.61M	335.4M	327.63M	356.86M	336.93M	336.86M	598.73M	503.12M
Equity Growth %	-0.03%	-0.09%	0.13%	0.13%	-0.02%	0.09%	-0.06%	-0%	0.78%	-0.16%
Book Value per Share	15.45	14.27	16.03	17.73	17.33	18.40	17.11	16.76	16.30	13.19
Total Shareholders' Equity	290.31M	263.48M	296.61M	335.4M	327.63M	356.86M	336.93M	336.86M	598.73M	503.12M
Common Stock	1.87M	1.78M	1.83M	1.86M	1.9M	1.94M	1.98M	2.02M	3.72M	3.85M
Retained Earnings	62.55M	64.18M	70.4M	87.08M	57.75M	59.38M	21M	1.25M	-150.14M	-276.14M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-6.23M	-6.58M	3.79M	3.3M	-3.04M	3.25M	0	-1.38M	-1.29M	-4.3M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	43.22M	44.71M	53.34M	49.92M	32.03M	74.27M	18.48M	-11.54M	-45.75M	25.79M
Operating CF Margin %	0.11%	0.11%	0.12%	0.11%	0.07%	0.18%	0.04%	-0.03%	-0.06%	0.03%
Operating CF Growth %	-0.15%	0.03%	0.19%	-0.06%	-0.36%	1.32%	-0.75%	-1.62%	-2.97%	1.56%
Net Income	-2.81M	3.06M	6.22M	13.81M	-28.46M	2.52M	-38.38M	-19.75M	-151.4M	-126M
Depreciation & Amortization	20.92M	20.84M	20.12M	18.66M	24.7M	34.28M	33.09M	32.08M	60.6M	75.96M
Stock-Based Compensation	7.21M	15.97M	12.56M	18.93M	21.54M	16.21M	15.43M	18.44M	35.71M	32.45M
Deferred Taxes	-1.16M	10.46M	21.29M	-2.66M	1.39M	10.79M	24.48M	314K	579K	1.88M
Other Non-Cash Items	3.55M	6.47M	10.33M	8.18M	42.24M	-9.21M	1.95M	-13.39M	62.72M	60.74M
Working Capital Changes	15.51M	-12.09M	-17.18M	-7M	-29.38M	19.7M	-18.1M	-29.23M	-53.96M	-19.25M
Change in Receivables	-1.55M	392K	-6.56M	-3.71M	-11.04M	13.28M	-7.05M	-6.74M	-10.41M	-9.53M
Change in Inventory	3.14M	-5.28M	-15.64M	9.7M	-5.71M	-873K	619K	-18.13M	-58.05M	-5.55M
Change in Payables	3.01M	-1.77M	2.32M	-170K	2.14M	2.53M	4.25M	2.28M	8.64M	-5.57M
Cash from Investing+	-38.35M	-21.95M	-16.47M	-61M	-22.92M	-52.33M	-23.01M	-24.53M	-33.13M	-27.58M
Capital Expenditures	-27.9M	-18.33M	-16.95M	-15.26M	-20.52M	-17.09M	-19.59M	-23.16M	-62.05M	-34.88M
CapEx % of Revenue	0.07%	0.04%	0.04%	0.03%	0.04%	0.04%	0.04%	0.05%	0.08%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	4.8M	0	474K	-1.45M	-2.4M	-24.33M	-1.25M	0	-500K	-100K
Cash from Financing+	25.11M	-46.11M	3.54M	2.99M	-10.69M	3.25M	-3.62M	-78K	65.32M	50.71M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	32.98M	-2.41M	-4.25M	-4.11M	-21.87M	-4.03M	-11.91M	-1.82M	-7.75M	-9.94M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	15.32M	26.37M	36.39M	34.66M	11.51M	57.18M	-1.12M	-34.7M	-107.8M	-9.09M
FCF Margin %	0.04%	0.06%	0.08%	0.08%	0.03%	0.14%	-0%	-0.08%	-0.14%	-0.01%
FCF Growth %	-0.53%	0.72%	0.38%	-0.05%	-0.67%	3.97%	-1.02%	-30.06%	-2.11%	0.92%
FCF per Share	0.82	1.43	1.97	1.83	0.61	2.95	-0.06	-1.73	-2.94	-0.24
FCF Conversion (FCF/Net Income)	-15.39x	14.63x	8.57x	3.61x	-1.13x	29.51x	-0.48x	0.58x	0.30x	-0.20x
Interest Paid	852K	672K	811K	0	0	0	0	0	0	0
Taxes Paid	3.16M	4.42M	3.27M	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.95%	1.1%	2.22%	4.37%	-8.59%	0.74%	-11.06%	-5.86%	-32.36%	-22.87%
Return on Invested Capital (ROIC)	2.84%	7.01%	13.93%	9.38%	-5.16%	-1.66%	-2.23%	-3.42%	-21.07%	-9.9%
Gross Margin	78.18%	78.56%	78.55%	78.67%	78.13%	74.94%	75.26%	73.18%	65.13%	68.28%
Net Margin	-0.71%	0.75%	1.43%	3.05%	-6.19%	0.62%	-8.26%	-4.29%	-20.28%	-15.76%
Debt / Equity	-	-	-	-	0.07x	0.07x	0.07x	0.06x	0.20x	0.36x
Interest Coverage	18.93x	-	98.10x	36.35x	-153.97x	-2.52x	-4.53x	-10.30x	-16.12x	-2.86x
FCF Conversion	-15.39x	14.63x	8.57x	3.61x	-1.13x	29.51x	-0.48x	0.58x	0.30x	-0.20x
Revenue Growth	-1.44%	3.35%	5.87%	4.43%	1.53%	-11.61%	14.25%	-0.81%	62.06%	7.08%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Global Spine	-	-	-	-	-	-	-	353.17M	631.32M	675.31M
Global Spine Growth	-	-	-	-	-	-	-	-	78.76%	6.97%
Global Orthopedics	-	-	-	-	-	-	-	107.54M	115.32M	124.18M
Global Orthopedics Growth	-	-	-	-	-	-	-	-	7.24%	7.68%
Bone Growth Therapies	-	-	-	195.19M	197.18M	171.4M	187.45M	187.25M	-	-
Bone Growth Therapies Growth	-	-	-	-	1.02%	-13.08%	9.37%	-0.11%	-	-
Spinal Implants	-	-	-	72.14M	94.54M	94.86M	115.09M	109.55M	-	-
Spinal Implants Growth	-	-	-	-	31.06%	0.33%	21.33%	-4.82%	-	-
Biologics	59.83M	57.91M	62.72M	59.67M	65.5M	55.48M	56.42M	56.38M	-	-
Biologics Growth	-	-3.21%	8.31%	-4.87%	9.77%	-15.29%	1.69%	-0.07%	-	-
Orthofix Extremities	-	-	-	28.36M	-	-	-	-	-	-
Orthofix Extremities Growth	-	-	-	-	-	-	-	-	-	-
Bio Stim	164.96M	176.56M	185.9M	-	-	-	-	-	-	-
Bio Stim Growth	-	7.04%	5.29%	-	-	-	-	-	-	-
Extremity Fixation	96.03M	102.68M	103.24M	-	-	-	-	-	-	-
Extremity Fixation Growth	-	6.92%	0.54%	-	-	-	-	-	-	-
Spine Fixation	75.67M	72.63M	81.96M	-	-	-	-	-	-	-
Spine Fixation Growth	-	-4.01%	12.84%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other Countries	50.44M	54.55M	52.54M	50.9M	47.99M	39.12M	42.5M	44.99M	65.83M	66.39M
Other Countries Growth	-	8.16%	-3.70%	-3.12%	-5.71%	-18.50%	8.64%	5.86%	46.32%	0.86%
ITALY	-	16.66M	17.06M	19.33M	19.56M	18.73M	20.19M	19.1M	20.06M	21M
ITALY Growth	-	-	2.37%	13.32%	1.18%	-4.23%	7.76%	-5.39%	5.04%	4.69%
FRANCE	-	-	-	-	-	-	10.47M	10.38M	11.1M	13.38M
FRANCE Growth	-	-	-	-	-	-	-	-0.94%	6.93%	20.63%
DELAWARE	-	-	-	11.61M	12.69M	11.94M	13.72M	11.57M	11.47M	9M
DELAWARE Growth	-	-	-	-	9.32%	-5.90%	14.87%	-15.65%	-0.88%	-21.48%
BRAZIL	-	11.33M	10.36M	7.12M	7.68M	2.35M	5.11M	5.67M	6.45M	5.71M
BRAZIL Growth	-	-	-8.63%	-31.25%	7.94%	-69.46%	117.64%	10.96%	13.83%	-11.55%
UNITED STATES	-	316.87M	345.14M	-	-	-	-	-	-	-
UNITED STATES Growth	-	-	8.92%	-	-	-	-	-	-	-
U S	305.5M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-
I T	15.65M	-	-	-	-	-	-	-	-	-
I T Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Orthofix Medical Inc. (OFIX) reported $818.1M in revenue for fiscal year 2024. This represents a 41% increase from $579.0M in 2011.

Orthofix Medical Inc. (OFIX) grew revenue by 7.1% over the past year. This is steady growth.

Orthofix Medical Inc. (OFIX) reported a net loss of $119.1M for fiscal year 2024.

Dividend & Returns

Orthofix Medical Inc. (OFIX) has a return on equity (ROE) of -22.9%. Negative ROE indicates the company is unprofitable.

Orthofix Medical Inc. (OFIX) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Orthofix Medical Inc. (OFIX) 10-Year Financial Performance & Capital Metrics

OFIX • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesSpinal Implants & Fusion Systems

Revenue $799M +7.1%
EBITDA -$25M +68.7%
Net Income -$126M +16.8%
EPS (Diluted) -3.30 +19.9%
Gross Margin 68.28% +4.8%
EBITDA Margin -3.07% +70.8%
Operating Margin -10.58% +43.2%
Net Margin -15.76% +22.3%
ROE -22.87% +29.3%
ROIC -9.9% +53.0%
Debt/Equity 0.36 +82.6%
Interest Coverage -2.86 +82.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 11.7%
✓Trading at only 1.1x book value

✗Weaknesses

✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y7.11%

5Y11.69%

3Y19.84%

TTM4.31%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.5%

ROCE

10Y Avg-1.62%

5Y Avg-8.61%

3Y Avg-13.16%

Latest-11.4%

Peer Comparison

Spinal Implants & Fusion Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GMEDGlobus Medical, Inc.	10.46B	93.89	125.19	60.62%	15.3%	9.63%	3.87%	0.13
TNONTenon Medical, Inc.	10.6M	0.95	-0.08	11.92%	-396.26%	-267.01%		0.07
BBLGBone Biologics Corporation	3M	1.67	-0.35			-65.59%
OFIXOrthofix Medical Inc.	570.24M	14.40	-4.36	7.08%	-14.56%	-26.92%		0.36
XTNTXtant Medical Holdings, Inc.	91M	0.65	-5.42	28.44%	1.32%	3.48%		0.82
ATECAlphatec Holdings, Inc.	2.59B	17.46	-15.45	26.81%	-21.29%	-13.47%		64.65
SIBNSI-BONE, Inc.	762.82M	17.58	-23.44	20.37%	-11.24%	-12.64%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	396.49M	409.79M	433.82M	453.04M	459.95M	406.56M	464.48M	460.71M	746.64M	799.49M
Revenue Growth %	-0.01%	0.03%	0.06%	0.04%	0.02%	-0.12%	0.14%	-0.01%	0.62%	0.07%
Cost of Goods Sold+	86.53M	87.85M	93.04M	96.63M	100.61M	101.89M	114.91M	123.54M	260.37M	253.61M
COGS % of Revenue	0.22%	0.21%	0.21%	0.21%	0.22%	0.25%	0.25%	0.27%	0.35%	0.32%
Gross Profit+	309.96M	321.94M	340.79M	356.41M	359.35M	304.67M	349.56M	337.17M	486.27M	545.88M
Gross Margin %	0.78%	0.79%	0.79%	0.79%	0.78%	0.75%	0.75%	0.73%	0.65%	0.68%
Gross Profit Growth %	0.02%	0.04%	0.06%	0.05%	0.01%	-0.15%	0.15%	-0.04%	0.44%	0.12%
Operating Expenses+	291.63M	284.49M	302.46M	323.25M	378.13M	310.94M	357.88M	350.44M	625.38M	630.5M
OpEx % of Revenue	0.74%	0.69%	0.7%	0.71%	0.82%	0.76%	0.77%	0.76%	0.84%	0.79%
Selling, General & Admin	265.24M	255.69M	272.76M	290.03M	309.28M	272.38M	290.67M	308.78M	530.39M	532.52M
SG&A % of Revenue	0.67%	0.62%	0.63%	0.64%	0.67%	0.67%	0.63%	0.67%	0.71%	0.67%
Research & Development	26.39M	28.8M	29.7M	33.22M	34.64M	39.06M	49.62M	49.06M	80.23M	73.64M
R&D % of Revenue	0.07%	0.07%	0.07%	0.07%	0.08%	0.1%	0.11%	0.11%	0.11%	0.09%
Other Operating Expenses	-259K	0	0	0	34.21M	-499K	17.59M	-7.4M	14.76M	24.34M
Operating Income+	9.26M	21.07M	40.81M	30.09M	-18.78M	-6.27M	-8.31M	-13.27M	-139.11M	-84.62M
Operating Margin %	0.02%	0.05%	0.09%	0.07%	-0.04%	-0.02%	-0.02%	-0.03%	-0.19%	-0.11%
Operating Income Growth %	-0.46%	1.28%	0.94%	-0.26%	-1.62%	0.67%	-0.33%	-0.6%	-9.48%	0.39%
EBITDA+	30.18M	41.91M	60.94M	48.75M	9.69M	28.01M	24.78M	18.81M	-78.55M	-24.56M
EBITDA Margin %	0.08%	0.1%	0.14%	0.11%	0.02%	0.07%	0.05%	0.04%	-0.11%	-0.03%
EBITDA Growth %	0.55%	0.39%	0.45%	-0.2%	-0.8%	1.89%	-0.12%	-0.24%	-5.18%	0.69%
D&A (Non-Cash Add-back)	20.92M	20.84M	20.12M	18.66M	28.48M	34.28M	33.1M	32.08M	60.56M	60.06M
EBIT	9.26M	35.44M	40.81M	22.89M	-26.93M	2.12M	-11.66M	-16.42M	-140.05M	-94.24M
Net Interest Income+	-489K	763K	-416K	-828K	-122K	-2.48M	-1.84M	-1.29M	-8.63M	-29.63M
Interest Income	0	763K	0	0	0	0	0	0	0	0
Interest Expense	489K	0	416K	828K	122K	2.48M	1.84M	1.29M	8.63M	29.63M
Other Income/Expense	-748K	-2.04M	-4.42M	-7.21M	-8.27M	5.9M	-5.18M	-4.44M	-9.57M	-39.26M
Pretax Income+	8.51M	19.02M	36.39M	22.89M	-27.05M	-368K	-13.49M	-17.71M	-148.68M	-123.88M
Pretax Margin %	0.02%	0.05%	0.08%	0.05%	-0.06%	-0%	-0.03%	-0.04%	-0.2%	-0.15%
Income Tax+	10.85M	15.53M	29.1M	9.07M	1.41M	-2.88M	24.88M	2.04M	2.72M	2.12M
Effective Tax Rate %	-0.33%	0.16%	0.17%	0.6%	1.05%	-6.84%	2.84%	1.12%	1.02%	1.02%
Net Income+	-2.81M	3.06M	6.22M	13.81M	-28.46M	2.52M	-38.38M	-19.75M	-151.4M	-126M
Net Margin %	-0.01%	0.01%	0.01%	0.03%	-0.06%	0.01%	-0.08%	-0.04%	-0.2%	-0.16%
Net Income Growth %	0.67%	2.09%	1.04%	1.22%	-3.06%	1.09%	-16.25%	0.49%	-6.67%	0.17%
Net Income (Continuing)	-2.34M	3.5M	7.29M	13.81M	-28.46M	2.52M	-38.38M	-19.75M	-151.4M	-126M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.15	0.17	0.34	0.73	-1.51	0.13	-1.95	-0.98	-4.12	-3.30
EPS Growth %	0.67%	2.13%	1%	1.15%	-3.07%	1.09%	-16%	0.5%	-3.2%	0.2%
EPS (Basic)	-0.15	0.17	0.34	0.75	-1.51	0.13	-1.95	-0.98	-4.12	-3.30
Diluted Shares Outstanding	18.8M	18.46M	18.5M	18.91M	18.9M	19.39M	19.69M	20.1M	36.73M	38.13M
Basic Shares Outstanding	18.8M	18.14M	18.12M	18.49M	18.9M	19.27M	19.69M	20.1M	36.73M	38.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	212.25M	194.37M	251.8M	244.64M	260.55M	270.38M	269.52M	255.99M	420.44M	433.29M
Cash & Short-Term Investments	63.66M	39.57M	81.16M	69.62M	69.72M	96.29M	87.85M	50.7M	33.11M	83.24M
Cash Only	63.66M	39.57M	81.16M	69.62M	69.72M	96.29M	87.85M	50.7M	33.11M	83.24M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	59.84M	57.85M	63.44M	77.75M	86.81M	72.42M	78.56M	82.86M	128.1M	134.71M
Days Sales Outstanding	55.09	51.53	53.37	62.64	68.88	65.02	61.73	65.64	62.62	61.5
Inventory	57.56M	63.35M	81.33M	76.85M	82.4M	84.64M	82.97M	100.15M	222.17M	189.45M
Days Inventory Outstanding	242.83	263.18	319.07	290.28	298.93	303.19	263.55	295.88	311.45	272.67
Other Current Assets	0	14.37M	0	2.57M	684K	530K	0	22.28M	37.07M	25.88M
Total Non-Current Assets+	187.97M	177.73M	153.55M	222M	235.07M	255.48M	207.1M	202.64M	504.87M	460.01M
Property, Plant & Equipment	52.31M	48.92M	45.14M	42.84M	62.73M	63.61M	59.25M	58.23M	159.06M	139.8M
Fixed Asset Turnover	7.58x	8.38x	9.61x	10.58x	7.33x	6.39x	7.84x	7.91x	4.69x	5.72x
Goodwill	53.56M	53.56M	53.56M	72.4M	71.18M	84.02M	71.32M	71.32M	194.93M	194.93M
Intangible Assets	5.3M	7.46M	10.46M	51.9M	54.14M	60.52M	52.67M	47.39M	117.49M	98.8M
Long-Term Investments	321K	321K	0	219K	0	0	0	0	0	0
Other Non-Current Assets	19.17M	20.14M	21.07M	21.42M	11.91M	22.29M	22.09M	25.7M	33.39M	26.47M
Total Assets+	400.22M	372.1M	405.35M	466.64M	495.62M	525.86M	476.62M	458.63M	925.32M	893.29M
Asset Turnover	0.99x	1.10x	1.07x	0.97x	0.93x	0.77x	0.97x	1.00x	0.81x	0.89x
Asset Growth %	0.02%	-0.07%	0.09%	0.15%	0.06%	0.06%	-0.09%	-0.04%	1.02%	-0.03%
Total Current Liabilities+	81.99M	83.44M	79.41M	85.91M	84.88M	103.9M	105.83M	83.62M	165.22M	168.63M
Accounts Payable	11.21M	14.35M	18.11M	17.99M	19.89M	23.12M	26.46M	27.6M	58.36M	48.8M
Days Payables Outstanding	47.28	59.63	71.05	67.95	72.15	82.82	84.04	81.54	81.81	70.24
Short-Term Debt	0	0	0	0	0	0	0	0	1.25M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	5.18M	3.54M	9.63M	46.31M	48.79M	24.73M	21.99M	0	1M	7.1M
Current Ratio	2.59x	2.33x	3.17x	2.85x	3.07x	2.60x	2.55x	3.06x	2.54x	2.57x
Quick Ratio	1.89x	1.57x	2.15x	1.95x	2.10x	1.79x	1.76x	1.86x	1.20x	1.45x
Cash Conversion Cycle	250.63	255.08	301.39	284.97	295.67	285.39	241.24	279.99	292.26	263.93
Total Non-Current Liabilities+	27.92M	25.18M	29.34M	45.34M	83.11M	65.1M	33.86M	38.15M	161.36M	221.54M
Long-Term Debt	0	0	0	0	0	0	0	0	93.11M	157.01M
Capital Lease Obligations	0	0	0	0	20.65M	22.34M	19.89M	19.24M	18.53M	17.84M
Deferred Tax Liabilities	0	0	0	0	11.99M	0	0	0	0	0
Other Non-Current Liabilities	27.92M	25.18M	29.34M	45.34M	62.46M	42.76M	13.97M	18.91M	49.72M	46.69M
Total Liabilities	109.91M	108.63M	108.75M	131.24M	167.99M	169M	139.69M	121.77M	326.58M	390.17M
Total Debt+	0	0	0	0	22.85M	24.94M	24.31M	21.53M	117.07M	179.63M
Net Debt	-63.66M	-39.57M	-81.16M	-69.62M	-46.87M	-71.35M	-63.53M	-29.17M	83.97M	96.39M
Debt / Equity	-	-	-	-	0.07x	0.07x	0.07x	0.06x	0.20x	0.36x
Debt / EBITDA	-	-	-	-	2.36x	0.89x	0.98x	1.14x	-	-
Net Debt / EBITDA	-2.11x	-0.94x	-1.33x	-1.43x	-4.84x	-2.55x	-2.56x	-1.55x	-	-
Interest Coverage	18.93x	-	98.10x	36.35x	-153.97x	-2.52x	-4.53x	-10.30x	-16.12x	-2.86x
Total Equity+	290.31M	263.48M	296.61M	335.4M	327.63M	356.86M	336.93M	336.86M	598.73M	503.12M
Equity Growth %	-0.03%	-0.09%	0.13%	0.13%	-0.02%	0.09%	-0.06%	-0%	0.78%	-0.16%
Book Value per Share	15.45	14.27	16.03	17.73	17.33	18.40	17.11	16.76	16.30	13.19
Total Shareholders' Equity	290.31M	263.48M	296.61M	335.4M	327.63M	356.86M	336.93M	336.86M	598.73M	503.12M
Common Stock	1.87M	1.78M	1.83M	1.86M	1.9M	1.94M	1.98M	2.02M	3.72M	3.85M
Retained Earnings	62.55M	64.18M	70.4M	87.08M	57.75M	59.38M	21M	1.25M	-150.14M	-276.14M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-6.23M	-6.58M	3.79M	3.3M	-3.04M	3.25M	0	-1.38M	-1.29M	-4.3M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	43.22M	44.71M	53.34M	49.92M	32.03M	74.27M	18.48M	-11.54M	-45.75M	25.79M
Operating CF Margin %	0.11%	0.11%	0.12%	0.11%	0.07%	0.18%	0.04%	-0.03%	-0.06%	0.03%
Operating CF Growth %	-0.15%	0.03%	0.19%	-0.06%	-0.36%	1.32%	-0.75%	-1.62%	-2.97%	1.56%
Net Income	-2.81M	3.06M	6.22M	13.81M	-28.46M	2.52M	-38.38M	-19.75M	-151.4M	-126M
Depreciation & Amortization	20.92M	20.84M	20.12M	18.66M	24.7M	34.28M	33.09M	32.08M	60.6M	75.96M
Stock-Based Compensation	7.21M	15.97M	12.56M	18.93M	21.54M	16.21M	15.43M	18.44M	35.71M	32.45M
Deferred Taxes	-1.16M	10.46M	21.29M	-2.66M	1.39M	10.79M	24.48M	314K	579K	1.88M
Other Non-Cash Items	3.55M	6.47M	10.33M	8.18M	42.24M	-9.21M	1.95M	-13.39M	62.72M	60.74M
Working Capital Changes	15.51M	-12.09M	-17.18M	-7M	-29.38M	19.7M	-18.1M	-29.23M	-53.96M	-19.25M
Change in Receivables	-1.55M	392K	-6.56M	-3.71M	-11.04M	13.28M	-7.05M	-6.74M	-10.41M	-9.53M
Change in Inventory	3.14M	-5.28M	-15.64M	9.7M	-5.71M	-873K	619K	-18.13M	-58.05M	-5.55M
Change in Payables	3.01M	-1.77M	2.32M	-170K	2.14M	2.53M	4.25M	2.28M	8.64M	-5.57M
Cash from Investing+	-38.35M	-21.95M	-16.47M	-61M	-22.92M	-52.33M	-23.01M	-24.53M	-33.13M	-27.58M
Capital Expenditures	-27.9M	-18.33M	-16.95M	-15.26M	-20.52M	-17.09M	-19.59M	-23.16M	-62.05M	-34.88M
CapEx % of Revenue	0.07%	0.04%	0.04%	0.03%	0.04%	0.04%	0.04%	0.05%	0.08%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	4.8M	0	474K	-1.45M	-2.4M	-24.33M	-1.25M	0	-500K	-100K
Cash from Financing+	25.11M	-46.11M	3.54M	2.99M	-10.69M	3.25M	-3.62M	-78K	65.32M	50.71M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	32.98M	-2.41M	-4.25M	-4.11M	-21.87M	-4.03M	-11.91M	-1.82M	-7.75M	-9.94M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	15.32M	26.37M	36.39M	34.66M	11.51M	57.18M	-1.12M	-34.7M	-107.8M	-9.09M
FCF Margin %	0.04%	0.06%	0.08%	0.08%	0.03%	0.14%	-0%	-0.08%	-0.14%	-0.01%
FCF Growth %	-0.53%	0.72%	0.38%	-0.05%	-0.67%	3.97%	-1.02%	-30.06%	-2.11%	0.92%
FCF per Share	0.82	1.43	1.97	1.83	0.61	2.95	-0.06	-1.73	-2.94	-0.24
FCF Conversion (FCF/Net Income)	-15.39x	14.63x	8.57x	3.61x	-1.13x	29.51x	-0.48x	0.58x	0.30x	-0.20x
Interest Paid	852K	672K	811K	0	0	0	0	0	0	0
Taxes Paid	3.16M	4.42M	3.27M	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.95%	1.1%	2.22%	4.37%	-8.59%	0.74%	-11.06%	-5.86%	-32.36%	-22.87%
Return on Invested Capital (ROIC)	2.84%	7.01%	13.93%	9.38%	-5.16%	-1.66%	-2.23%	-3.42%	-21.07%	-9.9%
Gross Margin	78.18%	78.56%	78.55%	78.67%	78.13%	74.94%	75.26%	73.18%	65.13%	68.28%
Net Margin	-0.71%	0.75%	1.43%	3.05%	-6.19%	0.62%	-8.26%	-4.29%	-20.28%	-15.76%
Debt / Equity	-	-	-	-	0.07x	0.07x	0.07x	0.06x	0.20x	0.36x
Interest Coverage	18.93x	-	98.10x	36.35x	-153.97x	-2.52x	-4.53x	-10.30x	-16.12x	-2.86x
FCF Conversion	-15.39x	14.63x	8.57x	3.61x	-1.13x	29.51x	-0.48x	0.58x	0.30x	-0.20x
Revenue Growth	-1.44%	3.35%	5.87%	4.43%	1.53%	-11.61%	14.25%	-0.81%	62.06%	7.08%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Global Spine	-	-	-	-	-	-	-	353.17M	631.32M	675.31M
Global Spine Growth	-	-	-	-	-	-	-	-	78.76%	6.97%
Global Orthopedics	-	-	-	-	-	-	-	107.54M	115.32M	124.18M
Global Orthopedics Growth	-	-	-	-	-	-	-	-	7.24%	7.68%
Bone Growth Therapies	-	-	-	195.19M	197.18M	171.4M	187.45M	187.25M	-	-
Bone Growth Therapies Growth	-	-	-	-	1.02%	-13.08%	9.37%	-0.11%	-	-
Spinal Implants	-	-	-	72.14M	94.54M	94.86M	115.09M	109.55M	-	-
Spinal Implants Growth	-	-	-	-	31.06%	0.33%	21.33%	-4.82%	-	-
Biologics	59.83M	57.91M	62.72M	59.67M	65.5M	55.48M	56.42M	56.38M	-	-
Biologics Growth	-	-3.21%	8.31%	-4.87%	9.77%	-15.29%	1.69%	-0.07%	-	-
Orthofix Extremities	-	-	-	28.36M	-	-	-	-	-	-
Orthofix Extremities Growth	-	-	-	-	-	-	-	-	-	-
Bio Stim	164.96M	176.56M	185.9M	-	-	-	-	-	-	-
Bio Stim Growth	-	7.04%	5.29%	-	-	-	-	-	-	-
Extremity Fixation	96.03M	102.68M	103.24M	-	-	-	-	-	-	-
Extremity Fixation Growth	-	6.92%	0.54%	-	-	-	-	-	-	-
Spine Fixation	75.67M	72.63M	81.96M	-	-	-	-	-	-	-
Spine Fixation Growth	-	-4.01%	12.84%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other Countries	50.44M	54.55M	52.54M	50.9M	47.99M	39.12M	42.5M	44.99M	65.83M	66.39M
Other Countries Growth	-	8.16%	-3.70%	-3.12%	-5.71%	-18.50%	8.64%	5.86%	46.32%	0.86%
ITALY	-	16.66M	17.06M	19.33M	19.56M	18.73M	20.19M	19.1M	20.06M	21M
ITALY Growth	-	-	2.37%	13.32%	1.18%	-4.23%	7.76%	-5.39%	5.04%	4.69%
FRANCE	-	-	-	-	-	-	10.47M	10.38M	11.1M	13.38M
FRANCE Growth	-	-	-	-	-	-	-	-0.94%	6.93%	20.63%
DELAWARE	-	-	-	11.61M	12.69M	11.94M	13.72M	11.57M	11.47M	9M
DELAWARE Growth	-	-	-	-	9.32%	-5.90%	14.87%	-15.65%	-0.88%	-21.48%
BRAZIL	-	11.33M	10.36M	7.12M	7.68M	2.35M	5.11M	5.67M	6.45M	5.71M
BRAZIL Growth	-	-	-8.63%	-31.25%	7.94%	-69.46%	117.64%	10.96%	13.83%	-11.55%
UNITED STATES	-	316.87M	345.14M	-	-	-	-	-	-	-
UNITED STATES Growth	-	-	8.92%	-	-	-	-	-	-	-
U S	305.5M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-
I T	15.65M	-	-	-	-	-	-	-	-	-
I T Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Orthofix Medical Inc. (OFIX) reported $818.1M in revenue for fiscal year 2024. This represents a 41% increase from $579.0M in 2011.

Orthofix Medical Inc. (OFIX) grew revenue by 7.1% over the past year. This is steady growth.

Orthofix Medical Inc. (OFIX) reported a net loss of $119.1M for fiscal year 2024.

Dividend & Returns

Orthofix Medical Inc. (OFIX) has a return on equity (ROE) of -22.9%. Negative ROE indicates the company is unprofitable.

Orthofix Medical Inc. (OFIX) had negative free cash flow of $2.9M in fiscal year 2024, likely due to heavy capital investments.